Aclaris makes a deal, aims to raise $80M; Emmecell’s Ph1 update in corneal edema

Plus, news about Keymed Bio­sciences, Ouro Med­i­cines, Re­code, In­tel­lia, Quell, VBI Vac­cines and Zai Lab:

Aclaris adds two an­ti-TSLP pro­grams, seeks $80M: The new pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.